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Abstract
A new N-methyl D aspartate neurotransmitter receptor interacting protein has been identified by yeast two-hybrid screening of 
a mouse brain cDNA library. C-terminal binding protein 1 (CtBP1) was shown to associate with the intracellular C-terminal 
regions of the N-methyl D aspartate receptor subunits GluN2A and GluN2D but not with GluN1-1a cytoplasmic C-terminal 
region. In yeast mating assays using a series of GluN2A C-terminal truncations, it was demonstrated that the CtBP1 binding 
domain was localized to GluN2A 1157–1382. The GluN2A binding domain was identified to lie within the CtBP1 161–224 
region. CtBP1 co-immunoprecipitated with assembled GluN1/GluN2A receptors expressed in mammalian cells and also, in 
detergent extracts of adult mouse brain. Co-expression of CtBP1 with GluN1/GluN2A resulted in a significant decrease in 
receptor cell surface expression. The family of C-terminal binding proteins function primarily as transcriptional co-repressors. 
However, they are also known to modulate intracellular membrane trafficking mechanisms. Thus the results reported herein 
describe a putative role for CtBP1 in the regulation of cell surface N-methyl D aspartate receptor expression.
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Abbreviations
Ade  Adenine
CtBP  C-terminal binding protein
Leu  Leucine
His  Histidine
MAGUK  Membrane associated guanylate kinase
NMDA  N-methyl-D-aspartate
PSD  Post-synaptic density
SAP  Synapse associated protein
Introduction
Excitatory N-methyl-D-aspartate (NMDA) neurotransmitter 
receptors are key brain proteins because of the central role 
they play in long term potentiation and long term depres-
sion, mechanisms of learning and memory; in synaptogen-
esis during the development of the central nervous system, 
and as a potential therapeutic target in neurodegenerative 
and psychiatric disorders that include stroke, neuropathic 
pain, epilepsy, schizophrenia, and Alzheimer disease [1, 2]. 
NMDA receptors are tetramers formed by the co-assembly 
of two copies of the obligatory GluN1 subunit together with 
either two copies of a single type of the four GluN2 subunits 
(i.e. GluN2A to GluN2D), a single copy of two types of the 
GluN2 subunit class, or a single copy of an GluN2 subunit 
together with one of the GluN3 class. The NMDA receptor 
subpopulations have distinct physiological and pharmaco-
logical properties, localizations and developmental profiles 
[3].
At synapses, NMDA receptors are integral compo-
nents of a macromolecular signalling complex [4]. The 
membrane associated guanylate kinase (MAGUK) fam-
ily of scaffolding proteins are key components linking 
NMDA receptors with intracellular signalling path-
ways. They bind via their PDZ1 and PDZ domains to a 
motif, ES(D/E)V that is common to all GluN2 subunit 
C-termini. However, the four members of the MAGUK 
family, post-synaptic density 95 (PSD95), chapsyn 110, 
synapse associated protein-102 (SAP102) and SAP97, 
have been shown to interact differently with each NMDA 
receptor subtype [5, 6]. Indeed, an SH3 binding domain 
within the GluN2A C-terminal tail was identified as a 
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subtype-specific PSD-95 binding site [7]. This differen-
tial PSD-95/GluN2A interaction may contribute to the 
observed differences between GlUN2A and GluN2B with 
respect to their distribution and lateral mobility [8].
Several reports have suggested that GluN2D-contain-
ing receptors are extra-synaptic [9–12]. This together 
with the findings that GluN2D-containing receptors inter-
acted differently with the MAGUK proteins [5, 6] and the 
fact that the GluN2D intracellular C-terminal tail contains 
multiple protein–protein interaction domains (Fig. 1), led 
to a yeast-two hybrid screen conducted with the aim to 
identify a GluN2D targeting protein. The screen revealed 
the identification of a novel, putative NMDA receptor 
interacting protein, C-terminal binding protein1 (CtBP1). 




For all NMDA receptor subunit constructs, amino acid 
numbering begins at the start methionine in the signal 
peptide. pCISGluN1-C2 and pCISGluN2A were as in [6]. 
pGW1PSD-95αc-Myc and pCMVneoSAP102c-Myc were 
kind gifts from Dr M. Sheng (Genentech Inc. USA). The 
full length mouse CtBP1 variant 1 clone was purchased 
from Genscript (Piscataway, New Jersey, USA). It was sub-
cloned into pCMV-4a, using EcoRI at the 5′ and HindIII 3′ 
end using primers 5′AAAA GAA TTC ATG GGC AGC TCC 
CAC TTG 3′ and 5′AAAA AAG CTT CAA CTG GTC ACT 
CGT ATG 3′ which generated when expressed, CtBP1 with 
a FLAG tag at the N-terminus.
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Fig. 1  A summary of cDNA library screening strategy and results. 
A Shows the intracellular C-terminal GluNR2D C-terminal domain 
highlighting putative protein–protein interaction domains. For B 
single colonies of AH109 yeast cells pre-transformed with pGB-
KT7GluNR2D 864–1323, pGBKT7GluNR2D 864–1318 or 
pGBKT7 were used to inoculate 5  ml—Trp selection media cul-
tures which were then grown at 30 °C for 48 h at 250 rpm. Proteins 
were extracted from the resulting yeast cell pellets and analysed by 
immunoblotting using anti-c-Myc antibodies. The gel layout is the 
same for both immunoblots where: lane 1 = untransformed AH109 
cells; lane 2 = pGBKT7 transformed AH109 cells and lane 3 = pGB-
KT7GluNR2D 864–1323  (GluN2Dc-Myc) or pGBKT7GluNR2D 
864–1323  (GluN2DTrunc) transformed AH109 cells. Arrows denote 
the positions of GluNR2D 864–1323 and GluNR2D 864–1318. The 
immunoblots are representative of n = 3 independent transformations. 
Molecular weight markers × 103 are shown on the right hand side. C 
Is a summary of the characteristics of two interacting clones. D A 
schematic diagram showing the interactions between GluNR2D 864–
1323 and GluNR2D 864–1318 and clones 37 and 47
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Yeast Two-Hybrid Expression Constructs
The DNAs encoding the C-terminal domain constructs 
GluN2D 864–1323 and GluN2D 864–1318 were generated 
by PCR from the appropriate mammalian expression con-
struct and subcloned in frame into the BamHI/EcoRI sites of 
the pGBKT7 yeast bait vector to generate pGBKT7GluND 
and  pGBT7GluN2DTrunc, i.e. the GluN2D C-terminal 
domain lacking the ESEV, PSD-95 membrane associated 
guanylate kinase (MAGUK) binding domain. The C-terminal 
constructs pGBKT7GluN1-1a 834–938; pGBKT7GluN2A 
(encoding GluN2A 838–1464);  pGBKT7GluN2A1460 
(i.e.  pGBKT7GluN2ATrunc);  pGBKT7GluN2A1441; 
 pGBKT7GluN2A1420;   pGBKT7GluN2A1420-ASDA; 
 pGBKT7GluN2A1382 and  pGBKT7GluN2A1157 were gen-
erated as in [7]. Expression of all constructs was verified by 
immunoblotting ([7] and Fig. 1).
Antibodies
Affinity-purified anti-GluN1 C2 (911–920); anti-GluN2A 
(44–58 Cys) and anti-GluN2A (1381–1394) antibodies were 
raised and characterized as previously reported [6]. Mouse 
monoclonal anti-FLAG M2 antibodies were from Sigma-
Aldrich (Poole, UK) and anti- c-Myc Clone 4A6 mouse 
monoclonal antibodies from Upstate USA Inc. (Charlottes-
ville, VA, USA). Anti-CtBP1 antibodies raised in mice were 
from Sigma-Aldrich (Poole, UK) where the antigen used was 
a glutathione S-transferase full length (i.e. 1–429) CtBP1 
fusion protein.
Yeast Two-Hybrid Screening
The mouse brain cDNA library was sourced from 200 
BALB/c males, aged 9–12 weeks, normal whole brains. 
The number of independent clones present was 3.5 × 106 
which had an average insert size of 2.0 kb and a range of 
0.4–4.0 kb. The library was amplified as instructed by 
the manufacturer (Clontech, a TakaraBio company, St-
Germain-en-Laye, France). The library was amplified so 
that each independent clone was represented at least three 
times thereby ensuring that rare clones were present. The 
number of independent clones in the amplified library was 
10.5 × 106. For the library screen, the method of [13] was fol-
lowed. Pre-transformed with pGBKT7GluN2D 864–1323, 
AH109 S. cerevisiae yeast cells were co-transformed with 
cDNA mouse brain library plasmid DNA and cultured on 
-Leu/-Trp/-His/-Ade selective dropout 2% (w/v) agar plates 
for 5–7 days at 30 °C. Resulting colonies were streaked onto 
fresh -Leu/-Trp/-His/-Ade plates every 4 days for a total of 
three times. Plasmid DNAs from colonies surviving this 
rigorous screen, i.e. encoding putative positive GluN2D 
864–1323 interactors, were isolated and characterised by 
yeast mating assays as below.
Yeast Two-Hybrid Interaction Mating Assays
Yeast two-hybrid interaction mating assays to verify pro-
tein–protein interactions were carried out for either pGB-
KT7GluN2D 864–1323; pGBKT7GluN2D 864–1318; 
pGBKT7GluN1-1a 834–938; pGBKT7GluN2A (encod-
ing GluN2A 838–1464); pGBKT7GluN2A 838–1460 
(i.e.  pGBKT7GluN2ATrunc); pGBKT7GluN2A 838–1441; 
pGBKT7GluN2A 838–1420; pGBKT7GluN2A 838–1420-
ASDA; pGBKT7GluN2A 838–1382; pGBKT7GluN2A 
838–1157 (bait constructs) and, pGADT7CtBP1 1–224 
and pGADT7CtBP1 161–306 (fish constructs) exactly as 
described in [7]. Positive and negative controls were always 
carried out in parallel. The positive control was AH109 S. 
cerevisiae cells pre-transformed with pTD1-1 and Y187 S. 
cerevisiae cells pre-transformed with pVA3-1. The negative 
controls were either empty pGBKT7- and pGADT7- vectors 
or empty fish or bait respectively to check for auto-activation 
of either the bait or fish constructs.
Mammalian Cell Transfections
Human embryonic kidney (HEK) 293 cells were cultured 
and transfected using the calcium phosphate method as pre-
viously described [6]. Cells were incubated post-transfection 
in the presence of 1 mM ketamine to prevent NMDA recep-
tor-mediated cytotoxicity [6]. HEK 293 cells were trans-
fected in parallel with either  CtBP1FLAG alone (10 µg) or, 
GluN1-C2 + GluN2A + either CtBP1, PSD-95 or SAP102 
clones. The ratio of DNAs for the transfections were GluN1: 
GluN2: CtBP1, PSD-95 or SAP102, 1:3:4 which corre-
sponded to 2.5 µg:7.5 µg:10 µg for a 20 µg total DNA for 
transfection of a 1 × 250 ml flask. For transfections where 
cell surface NMDA receptor expression was measured, HEK 
293 cells were subcultured overnight prior to transfection in 
poly-d-lysine (100 µg/ml)-coated 24-well dishes and 0.5 µg 
total plasmid DNA was used per well.
Immunoprecipitation Assays
HEK 293 cells were harvested 24 h post-transfection, cell 
homogenates prepared and solubilised for 1 h at 4 °C at a 
concentration of 1.5 mg protein/ml with solubilisation buffer 
(50 mM Tris-citrate, pH 7.4, 240 mM NaCl, 5 mM EDTA, 
5 mM EGTA, 1% (v/v) Triton X-100 containing benzami-
dine (1 µg/ml), bacitracin (1 µg/ml), soybean trypsin inhibi-
tor (1 µg/ml), chicken egg trypsin inhibitor (1 µg/ml) and 
phenylmethylsulphonyl fluoride (1 mM)). Samples were 
diluted to 1 mg protein/ml with the above solubilisation 
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buffer and solubilised material was collected by centrifuga-
tion at 100,000×g for 40 min at 4 °C. The detergent extracts 
were incubated with affinity-purified rabbit anti-GluN1 C2 
antibodies (5 µg) or protein A purified non-immune rabbit 
Ig (5 µg) as control overnight at 4 °C. Protein A Sepharose 
(25 µl) was added and samples incubated for 1 h at 4 °C. 
Immune pellets were collected by centrifugation for 15 s at 
600×g, washed with 3 × 1 ml solubilisation buffer and then 
analyzed by immunoblotting.
For immunoprecipitations from native tissue, the P2 
membrane fraction was made from adult rat brain minus 
the cerebellum and 1% (w/v) sodium deoxycholate detergent 
solubilised 100,000×g extracts were prepared as described 
[14]. Samples were incubated with anti-GluN1 C2 or non-
immune rabbit Ig primary antibodies for 16 h at 4 °C. Immu-
noprecipitations were completed as above.
Immunoblottting
Immunoblotting was performed as previously described 
using 25–50 µg protein/sample precipitated using the chlo-
roform/methanol method and SDS-PAGE under reducing 
conditions in 7.5% (w/v) polyacrylamide slab minigels all 
as previously described [5]. Primary antibodies used were: 
anti-GluN1 C2 (911–920), anti-GluN2A (1381–1394) or 
anti-FLAG M2 primary antibodies. Rabbit or mouse horse-
radish-linked secondary antibodies (GE Healthcare, Chal-
font St Giles, Bucks., UK) were used at a final dilution of 
1:2000 and immunoreactivities were detected using the ECL 
western blotting system.
Determination of NMDA Receptor Cell Surface Expression 
by ELISA
NMDA receptor cell surface expression was carried out 
by ELISA assay using affinity-purified antibodies directed 
against an extracellular epitope of GluN2A i.e. anti-
GluNR2A 44–58 Cys at a concentration of 0.125 µg/ml all 
exactly as described in [5].
Results and Discussion
cDNA Library Screening: Identification of a Putative 
NMDA GluN2D Interacting Protein
The screen of the mouse brain cDNA library with the bait, 
pGBKT7GluN2D 864–1323, yielded 240 positive interac-
tors. From these, 60 strong and 60 weak interactors were 
randomly selected and each were subjected to yeast mating 
assays. From the selected 120 clones, 20 (19 from the pool 
of strong interactors and 1 from the pool of weak interactors) 
were real interactors in the yeast mating assays. For these 20 
clones, each colony was analysed in triplicate to determine 
the presence of a cDNA insert, the size of the insert and 
if the insert was in frame with the activation domain. Ten 
clones satisfied these criteria. These were subsequently DNA 
sequenced. Within these ten, six clones were eliminated as 
they are known false positives leaving four final clones. It 
was found that clones 37 and 47 encoded the same protein 
and overlapped in the DNA sequence obtained. Database 
searches showed that they encoded CtBP1 161–306 (clone 
37) and CtBP1 1–224 (clone 47) (Fig. 1). Notably, dele-
tion of the GluN2D ESDV PSD-95 C-terminal binding 
domain did not affect the interaction with clones 37 and 47 
(Fig. 1d). There are five known isoforms of CtBP1 named 
CtBP1-I1-I5. Figure 2 shows the alignment of clones 37 and 
47 with the five CtBP1 isoforms. Clone 47 shares amino 
acid sequence identity with CtBP1-I1 and CtBP1-I3 whereas 
clone 37 shares amino acid sequence identity with all five 
CtBP1 isoforms. The CtBP1 amino acid sequence that is 
common to both clones, i.e. CtBP1 161–224 is identical 
across all five CtBP1 variants (Fig. 2).
CtBP1 1–224 and CtBP1 161–306 Associate 
with GluN2A: Refinement of GluN2A/CtBP1 
Interaction Site
The interaction between CtBP1 and NMDA receptor subu-
nits merited further study since CtBP1 1–224 and CtBP1 
161–306 were identified in a rigorous yeast two hybrid 
cDNA screen and importantly were overlapping with 
respect to the amino acid sequences they encoded. In the first 
instance, the specificity of CtBP1/NMDA receptor subunits 
was investigated using yeast mating assays with appropriate 
positive and negative controls. Firstly, it was found that both 
CtBP1 1–224 and CtBP1 161–306 both interacted with the 
C-terminal tail of GluN2A, i.e. GluN2A 838–1464, with a 
qualitatively similar affinity to GluN2D 864–1323 (Fig. 3). 
It was found that CtBP1 did not associate with the GuN1-1a 
C-terminal domain (Fig. 3).
Refinement of the CtBP1 binding site on GluN2A was 
determined using a series of GluN2A C-terminal deletion 
constructs. These GluN2A constructs were designed for pre-
vious studies in which a second GluN2A PSD-95 binding 
site was identified [7]. Truncation of GluN2A at amino acid 
1157 resulted in the loss of interaction between GluN2A 
and both CtBP1 1–224 and CtBP1 161–306. Although 
there were some qualitative differences in the strength of 
the association of GluN2A with CtBP1 1–224 and GluN2A 
with CtBP1 161–306, both showed similar profiles with the 
CtBP1 GluN2A binding site identified as lying between 
GluN2A 1157–1382 (Fig. 3). This region does not include 
the non-ESDV Src homology three domain-binding motif 
1382–1389 [7]. Since the original cDNA library screen 
identified CtBP1 as a GluN2D interacting protein, the 
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Fig. 2  An alignment of CtBP1 
and NR2D C-terminal domain 
interacting clones, clone 37 and 
clone 47. An alignment of the 
five known isoforms of CtBP1 
with putative interacting clones, 
37 and 47. The arrow denotes 
the overlapping region shared 
by clone 37 and clone 47
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intracellular, C-terminal amino acid sequences of GluN2A 
and GluN2D were compared aiming to identify common 
motifs. Figure 3c shows an alignment of the two sequences. 
Three conserved amino acid motifs are found between 
GluN2A and GluN2D i.e. KLXXXR; SXDX(I/L) and S(I/L)
XL (Fig. 3c).
CtBP1 Co‑immunoprecipitates with Assembled 
GluN1/GluN2A NMDA Receptors from Detergent 
Extracts of Receptors Expressed in HEK 293 Cells 
of Native Brain Tissue
To determine if full length CtBP1 co-associates with NMDA 
receptor complexes, FLAG-tagged full length CtBP1-I1 was 
co-expressed with GluN1/GluN2A in HEK 293 cells and 
immunoprecipitations were carried out using anti-GluN1 
C2 antibodies or non-immune Ig as a control. Anti-GluN1 
antibodies were selected for immunoprecipitations since 
CtBP1 does not associate with GluN1 (Fig. 3). Therefore, 
if anti-CtBP1 immunoreactivity was evident in immune 
pellets, it would demonstrate that CtBP1 associated with 
assembled GluN1/GluN2A NMDA receptors. The results 
of immunoblots of immune pellets are shown in Fig. 4. A 
band of  Mr ~ 120 kDa was evident in anti-GluN1 C2 immune 
pellets but not in non-immune Ig controls demonstrating 
successful immunoprecipitation. A band with  Mr ~ 180 kDa 
was detected in anti-GluN1 C2 but not non-immune Ig pel-
lets indicating immunoprecipitation of assembled GluN1/
GluN2A NMDA receptors. Anti-FLAG immunoreactivity, 
 Mr ~ 50 kDa was also detected in anti-GluN1 C2 but not 
control immune pellets thus demonstrating that full length 
CtBP1-I1 does indeed co-immunoprecipitate with assembled 
GluN1/GluN2A NMDA receptors (Fig. 4).
Immunoprecipitations were also carried out from deter-
gent extracts of adult rat brain. As for heterologous co-
expression of GluN1/GluN2A/CtBP1-I1, anti-GluN1 C2 
primary antibodies specifically immunoprecipitated GluN1 
and GluN2A immunoreactive bands (Fig.  4c). Further, 
anti-CtBP1 immunoreactivity was present in immune but 
not non-immune pellets. Immunoprecipitation with only 
anti-GluN1 antibodies does not distinguish between GluN1/
CtBP1 and GluN1/GluN2A/CtBP1 immunoprecipitated 
complexes. We cannot exclude the possibility that although 
CtBP1 does not interact directly with GluN1-1a in yeast mat-
ing assays, it may associate and thus co-immunoprecipitate 
with GluN1 from brain detergent extracts via an intermedi-
ary, brain protein. However, given the yeast mating assay 
























































Fig. 3  Identification of the GluN2A amino acid sequence that medi-
ates association with CtBP1 1–224 and C-tBP1 protein 161–306. A 
and B Y189 S. cerevisiae yeast cells transformed with C-terminal 
bait constructs, pGBKT7GluN1-1a 834–938, pGBKT7GluNR2A, 
pGBKT7GluNR2D 864–1323 or truncations, as shown of GluNR2A 
C-terminal bait constructs as shown and AH109 S. cerevisiae cells 
transformed with pGADT7CtBP1 1–224 or pGADT7CtBP1 161–
306 were mated and grown on -Leu/-Trp/-His/-Ade agar plates, and 
the number of diploid colonies counted after 7 days of incubation at 
30 °C all as described under “Experimental Procedures”. The figures 
depict the bait and fish constructs and the resulting diploid colonies.. 
The number of diploid colonies was semi-quantified by the number of 
colonies thus +++ = 500 +; ++ = 250–499; + = 1–241 and − = 0 col-
onies. C A schematic diagram highlighting possible protein–protein 
interaction motifs shared between GluNR2A and GluNR2D
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GluN1-1a, this seems unlikely. Thus it is a reasonable con-
clusion that in the brain and in heterologous expression sys-
tems, CtBP1 co-immunoprecipitates with native, assembled 
GluN1/GluN2A NMDA receptors.
Co‑expression of CtBP1 Results in a Decrease 
of GluN1/GluN2A Cell Surface Expression
There are four members of the CtBP family, (CtBP1, CtBP2, 
CtBP3/BARS and RIBEYE). The homologous proteins were 
originally identified as binding partners for the E1A-trans-
forming proteins and are now recognized to function primar-
ily as transcriptional co-repressors. CtBP1 and CtBP2 are 
both widely expressed in mammalian tissues including the 
brain (reviewed in [15, 16]). With respect to their subcel-
lular distribution, CtBP2 has a nuclear localization signal 
and accumulates within the nucleus whereas CtBP1 is found 
in both the cytoplasm and in the nucleus. In addition to the 
repressor function the family of CtBP proteins have been 
shown to have different cellular functions in Golgi mem-
branes, and in synaptic ribbons [17]. Since CtBP1 has been 
implicated in mechanisms of intracellular trafficking [18], 
thus it was of interest to determine what effect CtBP1 had 
on the cell surface expression of NMDA receptors. GluN1/
GluN2A NMDA receptors were co-expressed transiently 
in HEK 293 cells and cell surface expression measured by 
an ELISA using antibodies directed against the GluN2A 
extracellular domain. In parallel, GluN1/GluN2A were 
expressed with PSD-95 or SAP102 as positive and negative 
controls. The results are shown in Fig. 5. As previously pub-
lished co-expression with PSD-95 resulted in an enhanced 
GluN1/GluN2A surface expression of 175% ± 6 (n = 7), 
(p < 0.0001) whereas co-expression with SAP102 had no 
significant effect of receptor surface expression [5]. The 
values for SAP102 co-expression were: 99% ± 0.12 (n = 7), 
(p < 0.1). Co-expression with CtBP1 resulted in a decrease 
in GluN1/GluN2A surface expression, i.e. 58% ± 4 (n = 7), 
(p < 0.0001) with respect to control (Fig. 5).
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Fig. 4  CtBP1 co-immunoprecipitates with GluN2A expressed 
in HEK 293 cells and from native brain tissue. A and B HEK 293 
cells were either co-transfected with GluN1-1a/GluN2A/CtBP1FLAG 
clones or pCIS or the  CtBP1FLAG clones alone, cells cultured for 48 h, 
100,000×g detergent extracts (A) or cell homogenates (B) were pre-
pared and immunoprecipitations (A) or immunoblotting (B) carried 
out all as described in “Experimental Procedures”. Immunoprecipi-
tations were carried out using with anti-GluN1 C2 or non-immune 
Ig antibodies and immunoblots were probed with anti-GluN1 C2, 
anti-GluNR2A (1381–1394) and anti-FLAG antibodies as shown. 
The results are representative of n = 3 independent transfections. B 
Immunoblots of transfected cell homogenates were probed with anti-
CtBP antibodies. C Immunoprecipitations from 100,000×g detergent 
extracts of whole rat brain were carried out using anti-GluN1 C2 or 
non-immune Ig antibodies and immunoblots were probed with the 
antibodies as shown in the abscissa. The immunoblots are representa-
tive of n = 3 independent immunoprecipitations. For A and B the gel 
layout is the same where lane 1 = input; lane 2 = non-immune Ig pel-
let; lane 3 = anti = GluR1 C2 immune pellet. For C, lane 1 = HEK 
293 cells transfected with pCIS; lanes 2–4, homogenates of HEK 293 
cells transfected with the  CtBP1FLAG clone where lane 2 = µg protein; 
lane 3 = µg protein and lane 4 = µg protein Molecular weight mark-




















Fig. 5  Co-expression of CtBP1 with GluN1/GluN2A results in 
decreased cell surface expression. HEK 293 cells were co-trans-
fected with either GluNR1-C2 + GluN2A + either CtBP1, PSD-95 or 
SAP102 clones and cell surface expressed NMDA receptors meas-
ured by ELISA assay using either anti-NR2A 44–58 Cys affinity-puri-
fied antibodies. The results are expressed as the ratio of absorbance in 
the presence to the absence of respective PSD-95, SAP102 or CtBP. 
The results are the mean ± SEM of triplicate samples from n = 7 inde-




In summary, a novel protein–protein interaction between 
CtBP1 and GluN2A-containing NMDA receptors has 
been discovered. We have refined the sites of association 
between the two proteins. Further, we have shown that 
CtBP1 co-immunoprecipitates with assembled GluN1/
GluN2A receptors and importantly, expression of CtBP1 
with GluN1/GluN2A resulted in a decreased cell surface 
receptor expression. Co-immunoprecipitation does not 
show that two proteins interact directly but since the asso-
ciation of CtBP1 with NMDA receptor NR2 subunits was 
found by yeast two-hybrid interactions, this implies that 
the link between the two proteins is direct. Optimally how-
ever, an additional method such as pull down assays needs 
to be carried out to substantiate direct association between 
CtBP and NMDA receptors. Further, co-distribution stud-
ies are also essential. The original yeast two-hybrid screen 
indicated that CtBP1 associates with GluN2D-containing 
NMDA receptors. Preliminary yeast mating assays find-
ings revealed that this is also the case for GluN2B, i.e. 
C-terminal GluN2B domains interact with CtBP1 1–224 
and CtBP1 161–306. Further studies are required to deter-
mine if CtBP1 is universal with regard to NMDA receptor 
subtype association and regulation.
The primary function of CtBP1 is as a repressor of 
transcription but as described above, it is also implicated 
in intracellular trafficking mechanisms. In neuronal cells 
CtBP1 has a dual localization. It is found in the nucleus 
and importantly, it is enriched in synaptosomal fractions 
[19]. It may be speculated that CtBPs are involved in syn-
apse to nuclear signalling. Intriguingly however, CtBP 
proteins were shown to co-immunoprecipitate from brain 
extracts with neuronal nitric oxide synthase, a known 
downstream signalling pathway activated by glutamate and 
NMDA receptors [20]. CtBP expressed in Madin–Darby 
canine kidney cells has a primarily nuclear localization 
[20]. But when neuronal nitric oxide synthase is co-
expressed with CtBP, this resulted in a shift to a more 
cytosolic localization [20]. Further, there are examples of 
altered in CtBP expression in neurodegenerative condi-
tions in which NMDA receptor dysfunction is implicated 
(reviewed in [16]). Alternatively, it may just control mem-
brane trafficking of receptors. Future studies will yield fur-
ther insights into the functional significance of NMDA 
receptor/CtBP1 interactions.
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